Combining a targeted drug with radiation for lung cancer that has spread to the brain

This trial is testing whether combining adagrasib—a medication designed to target a specific mutation in lung cancer cells—with stereotactic radiosurgery (a very precise form of radiation) can effectively treat cancer that has spread to the brain. The study will enroll 30 patients with advanced lung cancer that carries a KRAS G12C mutation and has developed untreated tumors in the brain. Researchers want to see if this combination approach works better than either treatment alone.

When lung cancer spreads to the brain, it becomes much harder to treat, and patients have limited options. This medication is known to work against the specific genetic mutation found in some lung cancers, but it's not yet clear whether combining it with focused radiation therapy will improve how well it works for brain tumors.